morningstar

AVROBIO to Explore Strategic Alternatives

morningstar

AVROBIO Announces Leadership Transition

yahoo

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635

yahoo

AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

morningstar

AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

businesswire

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635

marketscreener

AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

businesswire

AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

biospace

AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II or Hunter Syndrome

marketscreener

AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference

businesswire

AVROBIO to Present at Two Upcoming Investor Conferences in November

marketscreener

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

yahoo

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

yahoo

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm

yahoo

BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO

yahoo

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

yahoo

AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting - Yahoo Finance

yahoo

AVROBIO, Inc. Upgraded to Buy: What Does It Mean for the Stock?